The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably will not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment of this invention relates to the antibodies and binding fragments thereof comprising the sequences of the VH, VL and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments thereof, e.g., antibody-drug conjugates, as well as chimeric antigen receptor T cells and NK cells based on the anti-FZD7 antibodies and binding fragments thereof. The invention further contemplates the use of the anti-FZD7 antibodies and binding fragments thereof for tissue engineering. Another embodiment of this invention relates to a transgenic mouse expressing the epitope of the anti-FZD7 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-FZD7 antibodies and binding fragments thereof (as well as the identified FZD7 epitope) for the diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer.La présente invention concerne des anticorps et des fragments correspondants présentant une spécificité de liaison pour FZD7, qui, de préférence, ninteragiront pas sensiblement avec (ne se lieront pas sensiblement à) dautres membres de la famille des FZD, et des procédés de fabrication desdits anticorps anti-FZD7 et des fragments de liaison correspondants. Un autre mode de réalisation de la présente invention concerne les anticorps et leurs fragments de liaison, comprenant les séquences des polypeptides VH, VL et/ou CDR décrits dans la description. Linvention concerne également des conjugués danticorps anti-FZD7 et de fragments de liaison correspondants, par exemple, des conjugués anticorps-médicament, ainsi que des lymphoc
